DEPARTMENT OF HEALTH - 17-Hydroxyprogesterone caproate - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2004-10-29 11:58:58 Pharmaceutical industry Research Pharmacology Therapeutics United States Public Health Service New Drug Application Approved Drug Products with Therapeutic Equivalence Evaluations Approved drug 17-Hydroxyprogesterone caproate Food and Drug Administration Pharmaceutical sciences Clinical research		DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 416,69 KB Share Document on Facebook

	August 13, 2014 Sylvia Mathews Burwell, Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, D.CDear Secretary Burwell: DocID: 19wW8 - View Document
	DISCUSSION RESOURCE GUIDE Progesterone Promotion What is 17P? 17 alpha-hydroxyprogesterone caproate (17P) is a synthetic form of progesterone that has been shown to reduce the recurrence of preterm birth (PTB) for women DocID: 19vZo - View Document
	[Federal Register: September 13, 2000 (Volume 65, NumberNotices] [PageFrom the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr13se00-81] -------------------------------------- DocID: 17M6C - View Document
	PDF Document DocID: 14tuc - View Document
	Strategies to prevent preterm birth DocID: 10MBe - View Document